Nabilone
(6AR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one
Drag to rotate. Structure from PubChem CID 5284592.
Background
Listing
- Schedules
- Schedule 7 to 8, conditions apply
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
The ingredient index links no registered medicine to Nabilone (register of 13 September 2026).
Counted through the register's ingredient index, which does not reach every record.
Regulatory status
Where S7 to S8 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 7: prohibited outside a government permit. At the most restrictive, Schedule 8: government-controlled, permit-only, patient-specific supply. The listings below say which applies to which form, strength or pack size.
Schedule S7 to S8, as the Consolidated Schedules list it.
Who may supply: The Director-General, to provide to a medical practitioner treating a particular patient, on conditions the Director-General determines; or, under the same permit system, a medical practitioner, analyst, researcher or veterinarian the Director-General has authorised, for treatment or prevention in a particular patient, or for education, analysis or research.
Consolidated Schedules listings for Nabilone
S8: Nabilone
Consolidated Schedules 06 July 2026, line 10942
S7: Nabilone
Consolidated Schedules 06 July 2026, line 10817
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.